NO20015972L - Screeningsmetoder for å endre dögnrytmeproteiner - Google Patents

Screeningsmetoder for å endre dögnrytmeproteiner

Info

Publication number
NO20015972L
NO20015972L NO20015972A NO20015972A NO20015972L NO 20015972 L NO20015972 L NO 20015972L NO 20015972 A NO20015972 A NO 20015972A NO 20015972 A NO20015972 A NO 20015972A NO 20015972 L NO20015972 L NO 20015972L
Authority
NO
Norway
Prior art keywords
alter
ability
directed
screening methods
phosphorylation
Prior art date
Application number
NO20015972A
Other languages
English (en)
Other versions
NO330241B1 (no
NO20015972D0 (no
Inventor
George Keesler
Cesare Mondadori
Zhengbin Yao
Fernando Camacho
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of NO20015972D0 publication Critical patent/NO20015972D0/no
Publication of NO20015972L publication Critical patent/NO20015972L/no
Publication of NO330241B1 publication Critical patent/NO330241B1/no

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Electrophonic Musical Instruments (AREA)
  • Peptides Or Proteins (AREA)
NO20015972A 1999-06-08 2001-12-06 Fremgangsmate for a identifisere forbindelser som endrer fosforylering av det humane klokkeproteinet hPERIODE1 (hPER1) NO330241B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32774599A 1999-06-08 1999-06-08
PCT/US2000/015633 WO2000075669A1 (en) 1999-06-08 2000-06-07 Screening methods for altering circadian rhythm proteins

Publications (3)

Publication Number Publication Date
NO20015972D0 NO20015972D0 (no) 2001-12-06
NO20015972L true NO20015972L (no) 2002-02-05
NO330241B1 NO330241B1 (no) 2011-03-14

Family

ID=23277866

Family Applications (3)

Application Number Title Priority Date Filing Date
NO20015972A NO330241B1 (no) 1999-06-08 2001-12-06 Fremgangsmate for a identifisere forbindelser som endrer fosforylering av det humane klokkeproteinet hPERIODE1 (hPER1)
NO20100430A NO20100430L (no) 1999-06-08 2010-03-23 Anvendelse av en forbindelse for fremstilling av et medikament for a endre den cirkadiske rytme hos et pattedyr
NO20100431A NO20100431L (no) 1999-06-08 2010-03-23 Fremgangsmate for a endre degradering av det humane klokkeproteinet hPeriode1 (hPER1)

Family Applications After (2)

Application Number Title Priority Date Filing Date
NO20100430A NO20100430L (no) 1999-06-08 2010-03-23 Anvendelse av en forbindelse for fremstilling av et medikament for a endre den cirkadiske rytme hos et pattedyr
NO20100431A NO20100431L (no) 1999-06-08 2010-03-23 Fremgangsmate for a endre degradering av det humane klokkeproteinet hPeriode1 (hPER1)

Country Status (15)

Country Link
US (1) US6555328B1 (no)
EP (1) EP1183541B1 (no)
JP (1) JP4583682B2 (no)
KR (1) KR100722176B1 (no)
AT (1) ATE322016T1 (no)
AU (1) AU767800B2 (no)
BR (1) BR0011437A (no)
CA (1) CA2375450C (no)
DE (1) DE60026998T2 (no)
IL (2) IL146729A0 (no)
MX (1) MXPA01011417A (no)
NO (3) NO330241B1 (no)
NZ (1) NZ514603A (no)
WO (1) WO2000075669A1 (no)
ZA (1) ZA200108962B (no)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6476188B1 (en) 1998-06-19 2002-11-05 The Rockefeller University Clock gene and methods of use thereof
US6436628B1 (en) 1998-06-19 2002-08-20 The Rockefeller University Methods of identifying an agent which modulates period and doubletime protein interaction
KR100722176B1 (ko) * 1999-06-08 2007-05-29 아벤티스 파마슈티칼스 인크. 일주기 리듬 단백질을 변화시키기 위한 스크리닝 방법
US7659387B1 (en) * 1999-11-18 2010-02-09 University Of Virginia Transgenic mammals introduced a Period 1 promoter that confers rhythmical expression
GB0103110D0 (en) * 2000-08-25 2001-03-28 Aventis Pharma Inc A membrane penetrating peptide encoded by a nuclear localization sequence from human period 1
EP1358315A4 (en) * 2001-01-11 2005-11-16 Univ Utah Res Found Identification of an advanced sleep phase syndrome gene in humans
AU2003278333A1 (en) * 2002-10-25 2004-05-13 University Of Surrey Polymorphism in the per3 gene as a indicator in the diagnosis and treatment of circadian rhythm sleep disorders
US20060134619A1 (en) * 2002-11-27 2006-06-22 Louis Ptacek Casein kinase i epsilon and casein kinase i delta and sleep in humans
AU2005277460A1 (en) * 2004-08-19 2006-03-02 Aventis Pharmaceuticals Inc. 3-arylthioindole-2-carboxamide derivatives and analogs thereof as inhibitors of casein kinase I epsilon
JO2629B1 (en) * 2004-08-19 2012-06-24 افينتيس فارما سوتيكالز انك Branched carboxylic acid amides containing thienobirol, carboxylic acid amides containing pyrolithiazole, and the like as kinase inhibitors casein epsilon
JO2724B1 (en) * 2004-08-19 2013-09-15 افينتس فارماسوتيكالز انك 3-Alternative-5 -6-Amino Alkyl Indole-2-Carboxyl Acid Amide and Related Isotopes as Casein Kinase Inhibitors
JP2009538597A (ja) * 2006-05-31 2009-11-12 独立行政法人放射線医学総合研究所 光誘導性周期的発現遺伝子及び体内時計システムに影響を与える物質のスクリーニング方法
JP5518479B2 (ja) * 2006-10-25 2014-06-11 ザ ロックフェラー ユニヴァーシティ Aβ関連障害の処置のための方法およびその組成物
FR2918986B1 (fr) 2007-07-19 2009-09-04 Sanofi Aventis Sa Derives de 6-cycloamino-3-(pyridazin-4-yl)imidazo[1,2-b]- pyridazine, leur preparation et leur application en therapeutique
CN105744948B (zh) * 2013-10-14 2020-03-24 南京大学 进食节律提前综合征的识别方法及其应用
KR101600144B1 (ko) * 2013-12-20 2016-03-04 서울대학교산학협력단 일주기 리듬 수면장애 및 시차 부적응에 대한 예방 또는 치료제 스크리닝 방법
BR112016016098A2 (pt) 2014-01-09 2017-08-08 Intracellular Therapies Inc Compostos orgânicos
WO2017083835A1 (en) * 2015-11-13 2017-05-18 The Trustees Of Columbia University In The City Of New York Inhibition of tor complex 2 increases immunity against bacterial infection
US20250066778A1 (en) * 2022-01-03 2025-02-27 The Johns Hopkins University Methods and materials for treating heart attack

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1157137A (ja) * 1997-08-28 1999-03-02 Sanyo Bussan Kk 遊技機用特別図柄表示装置
KR100246893B1 (ko) * 1997-12-29 2000-05-01 윤종용 전자렌지용 도어
AU3976099A (en) * 1998-05-07 1999-11-23 President & Fellows Of Harvard College, The Compositions and methods involving regulation of mammalian circadian rhythms
KR100722176B1 (ko) * 1999-06-08 2007-05-29 아벤티스 파마슈티칼스 인크. 일주기 리듬 단백질을 변화시키기 위한 스크리닝 방법

Also Published As

Publication number Publication date
KR100722176B1 (ko) 2007-05-29
AU5468900A (en) 2000-12-28
NO330241B1 (no) 2011-03-14
AU767800B2 (en) 2003-11-27
US6555328B1 (en) 2003-04-29
CA2375450C (en) 2009-04-28
NO20100431L (no) 2002-02-05
ATE322016T1 (de) 2006-04-15
KR20020033101A (ko) 2002-05-04
NO20100430L (no) 2002-02-05
JP4583682B2 (ja) 2010-11-17
JP2003501074A (ja) 2003-01-14
DE60026998T2 (de) 2007-04-05
BR0011437A (pt) 2002-03-05
NO20015972D0 (no) 2001-12-06
CA2375450A1 (en) 2000-12-14
WO2000075669A1 (en) 2000-12-14
EP1183541A1 (en) 2002-03-06
MXPA01011417A (es) 2002-06-04
ZA200108962B (en) 2003-01-30
IL146729A (en) 2007-06-17
IL146729A0 (en) 2002-07-25
DE60026998D1 (de) 2006-05-18
NZ514603A (en) 2003-10-31
EP1183541B1 (en) 2006-03-29

Similar Documents

Publication Publication Date Title
NO20100431L (no) Fremgangsmate for a endre degradering av det humane klokkeproteinet hPeriode1 (hPER1)
DE69938662D1 (de) Spurendetektion von analyten mit hilfe artifizieller olfaktometrie
EA200500856A1 (ru) Новые химические соединения
CY1110679T1 (el) Νουκλεοτιδικες και πρωτεϊνικες ακολουθιες γονιδιων nogo και μεθοδοι βασιζομενες σε αυτες
EA200100780A1 (ru) Антагонисты tweak и рецептора tweak и их использование для лечения иммунологических заболеваний
ATE279181T1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
DE69534360D1 (de) Zentrale Quelle von mehreren Wellenlängen
EA199900758A1 (ru) Малые молекулы, полезные при лечении воспалительных заболеваний
EA200301232A1 (ru) Новые соединения арилсульфонамида и их применение для лечения ожирения, диабета типа ii и нарушений центральной нервной системы
CY1106165T1 (el) Παραγωγα ινδολινονης για την τροποποιηση της c-kit πρωτεϊνικης τυροσινικης κινασης
CY1112055T1 (el) Συνθεσεις και μεθοδοι για την διαγνωση και θεραπευτικη αγωγη ογκου πνευμονα
EA200001244A1 (ru) Комбинационная терапия для лечения биполярных расстройств
EA200400241A1 (ru) Направленные к мишени мультимерные контрастные вещества, основанные на пептидах
DE69821667D1 (de) Kardioverter zur Behandlung von Vorhofflattern
ATE269303T1 (de) Arylpiperazinyl-cyclohexyl indolderivate zur behandlung von depressionen
EA200100012A1 (ru) Мостиковые инденопирролокарбазолы
EA200000920A1 (ru) Производные бициклических гидроксамовых кислот
DE69621799D1 (de) Verwendung von gabapentin und seine derivate in der behandlung von manie und bipolare störungen
DE60304695D1 (de) 7-ARYLSULFONAMID-2,3,4,5-TETRAHYDRO-1H-BENZOiDöAZEPINE MIT 5-HT6 REZEPTOR AFFINITÄT ZUR BEHANDLUNG VON ZENTRALNERVENSYSTEMERKRANKUNGEN
PT948604E (pt) Produtos e metodos relacionados com pyk2
ATE73995T1 (de) Verwendung von penicillamin zur behandlung von immunmangelkrankheiten.
EA200500603A1 (ru) ПРОИЗВОДНЫЕ [6,7-ДИГИДРО-5H-ИМИДАЗО[1,2-α]ИМИДАЗОЛ-3-СУЛЬФОНИЛАМИНО]ПРОПИОНАМИДА
CY1105380T1 (el) Προτιμωμενα τμηματα της νευρικης νηματικης πρωτεϊνης και μεθοδοι χρησης αυτων
ATE187442T1 (de) Tryptamine zur behandlung von störungen der circadianen rhythmik
ATE261724T1 (de) Antikonvulsive derivate zur behandlung von posttraumatischen stresserkrankungen

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees